The FDA approved an sBLA submitted by Johnson & Johnson’s Janssen Biotech for the addition of an indication for the treatment of pediatric patients 2 years and older with moderately to severely active Crohn’s disease for Stelara.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump names Erica Schwartz CDC Director
- Best ETFs to Invest In, According to AI Analyst, 4/16/2026
- Trump Trade: White House launches space nuclear initiative
- Johnson & Johnson Stock Forecast: Trending Bullish Among Analysts
- Drugmakers raised prices on hundreds of drugs, NBC News reports